Novel drugs in myeloma: Harnessing tumour biology to treat myeloma

Recent Results in Cancer Research

Volumn 183, Issue , 2011, Pages 151-187

  Boyd, Kevin D ^a   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; ATIPRIMOD; BHQ 880; BORTEZOMIB; CARFILZOMIB; CHEMOKINE RECEPTOR CCR ANTAGONIST; DENOSUMAB; DEXAMETHASONE; DICKKOPF 1 ANTIBODY; DOXORUBICIN; EVEROLIMUS; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; MLN 3897; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PERIFOSINE; PLACEBO; POMALIDOMIDE; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; SELUMETINIB; SORAFENIB; SOTATERCEPT; STEROID; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE DISEASE; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE REGULATION; CHROMATIN; CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; HOST RESISTANCE; HUMAN; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MULTIPLE MYELOMA; MYELOMA; MYELOMA CELL; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FOLDING; THROMBOEMBOLISM; TUMOR MICROENVIRONMENT;

ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHROMATIN; HISTONE DEACETYLASE INHIBITORS; HUMANS; JANUS KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPLE MYELOMA; NF-KAPPA B; PYRAZINES; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; WNT PROTEINS;

EID: 79955634077     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-85772-3_8     Document Type: Article

References (207)

1. Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T (2009) Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab 27(1):16-23
2. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM (2004) Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103(9):3271-3277 (Pubitemid 38525650)
3. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z (2005) Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93(1):70-80 (Pubitemid 41076255)
4. Anderson KC (2005) Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 42(4 suppl 4):S3-S8
5. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S (2006) Thalidomide derivative CC-4047 inhibits osteoclast formation by downregulation of PU.1. Blood 107(8):3098-3105
6. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr et al (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2):115-130 (Pubitemid 47199123)
7. Armand JP, Burnett AK, Drach J, Harousseau JL, Lowenberg B, San Miguel J (2007) The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. Oncologist 12(3):281-290 (Pubitemid 46556794)
8. Asano J, Abe M, Fujii S, Tanaka O, Mihara A, Nakamura S, Miki K, Kagawa K, Takeuchi K, Yata K, Hashimoto T, Ozaki S, Hiasa M, Matsumoto T (2007) The serine/threonine kinase pim-2 is a novel anti apoptotic mediator in myeloma cells. Blood 110:Abstract 243
9. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64(2):689-695 (Pubitemid 38120911)
10. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ et al (2009) The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113(18):4341-4351
11. Badros A, Philip S, Niesvizky R, Goloubeva O, Harris C, Zweibel J, Wright J, Burger A, Grant S, Baer MR, Egorin MJ (2007) Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (bort) in relapsed multiple myeloma (MM) patients. Blood 110:Abstract 1168
12. Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84(6):2008-2011 (Pubitemid 20016211)
13. Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K, Reed J, Faiman B, Ellis Y, Brand C, Srkalovic G, Andresen S, Knight R, Zeldis J, Hussein MA (2006) Lenali domide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17(12):1766-1771 (Pubitemid 44884050)
14. Beaupre DM, McCafferty-Grad J, Bahlis NJ, Boise LH, Lichtenheld MG (2003) Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leuk Lymphoma 44(12):2123-2134 (Pubitemid 37376366)
15. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG (2004) R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 3(2):179-186 (Pubitemid 39193692)
16. Bensinger W, Zonder J, Singhal S (2007) Phase I trial of huLuc63 in multiple myeloma. Blood 110:Abstract 1180
17. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1):296-303 (Pubitemid 40967205)
18. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8):3175-3184 (Pubitemid 38451696)
19. Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Scheffold C, Kroger M, Mesters RM, Berdel WE, Kienast J (2003) Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101(7):2775-2783 (Pubitemid 36857643)
20. Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS (2003) The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 17(2):451-457 (Pubitemid 36266924)
21. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10):1925-1932
22. Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld MG, Dalton WS, Beaupre DM (2005) Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 11(16):6057-6064 (Pubitemid 41170338)
23. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41(4):331-338
24. Campbell RA, Sanchez E, Chen H, Turker L, Trac O, Li M, Shalitin D, Gordon M, Pang S, Bonavida B, Said J, Plowman GD, Fuh G, Berenson J (2006) Anti-VEGF antibody treatment markedly inhibits tumor growth in SCID-hu models of human multiple myeloma. Blood 108:Abstract 846
25. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1):105-115 (Pubitemid 29077388)
26. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102(7):2615-2622 (Pubitemid 37193603)
27. Cavenagh JD, Yong J, Byrne J, Cavet J, Johnson P, Morgan G, Williams C, Akinaga S, Francis G, Kilborn J (2008) The safety, pharmacokinetics and pharmacodynamics of KW-2478, a novel Hsp90 antagonist, inpatients with B-cell malignancies: a first-in-man, phase I, multicentre, open-label, dose escalation study. Blood 112:Abstract 2777
28. Chanan-Khan A, Gharibo M, Jagannath S, Munshi N, Anderson KC, DePaolo D, P. Lee K, Miller K, Guild R, Zildjian S, Qin A (2008) Phase I study of IMGN901 in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. Blood 112:Abstract 3689
29. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC (2004) Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 104(12):3712-3721 (Pubitemid 39564449)
30. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, Kuban RJ, Lorentz H, Bommert K, Topp M, Kramer D, Muller-Hermelink HK, Einsele H, Greiner A, Bargou RC (2007) STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 109(2):720-728 (Pubitemid 46105974)
31. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87(3):1104-1112 (Pubitemid 26043538)
32. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8(5):407-419 (Pubitemid 41579835)
33. Chauhan D, Bianchi G, Anderson KC (2008) Targeting the UPS as therapy in multiple myeloma. BMC Biochem 9 suppl 1:S1
34. Chen J, Lee BH, Williams IR, Gilliland DG (2004) PKC412 effectively inhibits constitutively activated FGFR3 mutants in murine leukemia models and t(4;14) myeloma cell lines. Blood 104:Abstract 2448
35. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47(12):1466-1475 (Pubitemid 350115306)
36. Chim CS, Pang R, Fung TK, Choi CL, Liang R (2007) Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21(12):2527-2536 (Pubitemid 350148897)
37. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, Dogan A, Fonseca R (2008a) The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 111(3):1603-1609 (Pubitemid 351213451)
38. Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, Van Ness B, Fonseca R (2008b) Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 22(12):2280-2284
39. Cirstea D, Hideshima T, Pozzi S, Vallet S, Ikeda H, Santo L, Loferer H, Vaghela N, Okawa Y, Perrone G, Gorgun G, Calabrese E, Munshi NC, Anderson KC, Raje N (2008) RGB 286638, a novel multi-targeted small molecule inhibitor, induces multiple myeloma (MM) cell death through abrogation of CDKDependent and independent survival mechanisms. Blood 112:Abstract 2759
40. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, Gnoni A, Di Renzo N, Dammacco F, Tassone P, Ribatti D, Gambacorti-Passerini C, Vacca A (2008) Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 112(4):1346-1356
41. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ, Davies FE (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 110(7):2641-2649 (Pubitemid 47523188)
42. Davenport E, Zeisig A, Wiseglass L, Moore HE, Hockley SL, Gonzalez D, Smith E, Sharp S, Workman P, Morgan GJ, Davies F (2008) Inhibitors of heat shock protein 72 induction enhance apoptosis induced by HSP90 inhibitors. Blood 112:Abstract 2625
43. David E, Peng X, Barwick BG, Kaufman JL, Garlich JR, Lonial S (2008) SF1126, a novel P13K inhibitor results in downstream inhibition of the P13K axis and displays sequence specific synergy when combined with bortezomib in multiple myeloma cells. Blood 112:Abstract 5167
44. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1):210-216
45. Davies F, Moore H, Davenport E (2007a) Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Blood 110:Abstract 2505
46. Davies F, Ossenkopple G, Zachee P (2007b) A Phase I study of CHR-2797, an orally active aminopeptidase inhibitor in elderly and/or treatment refractory patients with acute myeloid leukaemia or multiple myeloma. Blood 110:Abstract 443
47. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B (2000) JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 109(4):823-828 (Pubitemid 30609763)
48. Demo SD, Aujay MA, Bennett MK, Lewis ER, Molineaux CJ, Kirk CJ (2009) Chronic administration of carfilzomib in experimental animals does not cause neurotoxicity. Clin Lymphoma Myeloma 8(7):Abstract 178
49. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M, Pals ST (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101(16):6122-6127 (Pubitemid 38520538)
50. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123-2132 (Pubitemid 350146107)
51. Evans R, Naber C, Steffler T, Checkland T, Keats J, Maxwell C, Perry T, Chau H, Belch A, Pilarski L, Reiman T (2008a) Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 49(3):559-569 (Pubitemid 351298342)
52. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T (2008b) The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 140(3):295-302
53. Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, Neumann F, Fenk B, Haas R, Kobbe G (2007) Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 48(12):2345-2351 (Pubitemid 350253466)
54. Frassanito MA, Cusmai A, Iodice G, Dammacco F (2001) Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97(2):483-489 (Pubitemid 32060334)
55. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A (2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104(13):4181-4187
56. Frost P, Shi Y, Hoang B, Lichtenstein A (2007) AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26(16):2255-2262 (Pubitemid 46572812)
57. Galli M, Salmoiraghi S, Golay J, Gozzini A, Bosi A, Crippa C, Rossi G, Pescosta N, Cortelazzo S, Sechi A, Oldoni T, Rambaldi A (2007) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results. Blood 110:Abstract 1175
58. Gaponova T, Misurin A, Mendeleeva L, Varlamova E, Parovichnikova E, Savchenko V (2008) Expression of XIAP in Multiple Myeloma Patients. Blood 112:Abstract 5118
59. Ghobrial I, Munshi N, Schlossman R (2008) Phase I trial of CCI-779 (temsirolimus) and weekly bortezomib in relapsed and/or refractory multiple myeloma. Blood 112:Abstract 3696
60. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, Anderson KC (1994) Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 84(9):3017-3025 (Pubitemid 24328093)
61. Gorgun G, Calabrese E, Mani M, Hideshima T, Ikeda H, Perrone G, Santo L, Cirstea D, Blotta S, Richardson PG, Ecsedy J, Anderson KC (2008). A novel aurora-a kinase inhibitor MLN8237 induces cytotoxicity and cell cycle arrest in experimental multiple myeloma models. Blood 112:Abstract 1719
62. Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T (2004) Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125(1):38-41 (Pubitemid 38453275)
63. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128(2):192-203
64. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24(3):425-436
65. Hembrough TA, Chen X, Burke PA, Swartz GM, Bengali K, Brokx R, LaVallee TM, Bray MR (2007) Inhibition of multiple myeloma tumor growth and FGFR3 by the aurora-angiogenesis inhibitor ENMD-981693. Blood 110:Abstract 1209
66. Hideshima T, Nakamura N, Chauhan D, Anderson KC (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20(42):5991-6000 (Pubitemid 32955041)
67. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC (2003a) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22(52):8386-8393 (Pubitemid 37523890)
68. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC (2003b) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101(4):1530-1534 (Pubitemid 36182530)
69. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC (2004) p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23(54):8766-8776 (Pubitemid 39593291)
70. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102(24):8567-8572 (Pubitemid 40862776)
71. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC (2006a) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107(10):4053-4062 (Pubitemid 43726814)
72. Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC (2006b) MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 12(19):5887-5894 (Pubitemid 44629622)
73. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Kramer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Mohler T et al (2009) Inhibition of aurora-kinases for tailored risk adapted treatment of multiple myeloma. Blood 113(18):4331-4340
74. Hrusovsky I, Heidtmann H (2005) Combination therapy of bortezomib with low-dose bendamustine in elderly patients with advanced multiple myeloma. Blood 106:Abstract 5122
75. Ikeda H, Hideshima T, Lutz R, Vallet S, Pozzi S, Santo L, Calabrese E, Dälken B, Uherek C, Aigner S, Osterroth F, Fultiniti M, Okawa Y, Perrone G, Gorgun G, Yasui H, Cristia D, Raje N, Munshi N, Richardson P, et al. (2008a) The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. Blood 112:Abstract 1716
76. Ikeda H, Hideshima T, Okawa Y, Vallet S, Pozzi S, Santo L, Gorgun G, Fulciniti M, Raje NS, Perrone G, Munshi N, Richardson P, Lannutti BJ, Puri KD, Giese NA, Anderson KC (2008b) CAL-101, a specific inhibitor of the p110 isoform of phosphatidylinositide 3-kinase induces cytotoxicity in multiple myeloma (MM). Blood 112:Abstarct 2753
77. Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC (2008) p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 141(5):598-606 (Pubitemid 351667613)
78. Jagannath S, Vij R, Stewart AK, Somlo G, Jakubowiak A, Reiman T, Trudel S, Taylor J, Fuhrman D, Cruickshank S, Schwartz R, Kunkel L, Siegel D, Consortium TMMR (2009) Phase II study of carfilzomib in patients with relapsed and refractory myeloma (PX-171-003). Clin Lymphoma Myeloma 8(7):Abstract 377
79. Jakubowiak A, Richardson P, Zimmerman T (2008) Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Blood 112:Abstract 3691
80. Jakubowiak AJ, Bensinger W, Zimmerman T, Chanan-Khan A, Singhal A, Siegel D, Anderson K (2009) Phase I study of Elotuzumab (HuLuc63) in combination wuth bortezomib in relapsed multiple myeloma. Clin Lymphoma Myeloma 8(7):Abstract 264
81. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P et al (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12(2):131-144 (Pubitemid 47208626)
82. Khan SB, Maududi T, Barton K, Ayers J, Alkan S (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125(2):156-161 (Pubitemid 38534966)
83. Khong T, Spencer A (2007) A new generation XIAP inhibitor induces apoptosis of human myeloma cells and synergises with conventional and novel anti-myeloma therapeutics. Blood 110:Abstract 4787
84. Khong T, Sharkey J, Spencer A (2008) The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 93(6):860-869 (Pubitemid 351821722)
85. Kim H-Y, Kim S-W, Lee H-J (2008) The CXCR4 antagonist AMD3100 stimulates the proliferation of plasma cells. Blood 112:Abstract 1701
86. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC (2007) 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 6(6):1718-1727 (Pubitemid 46954048)
87. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ (2008) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and non-specific proteasome inhibitors. Blood 113:4667-4676
88. Kurzrock R, Fayad L, Voorhees P, Furman RR, Lonial S, Borghaei H, Jagannath S, Sokol L, Cornfeld M, Qi M, Jiao T, Herring J, Qin X, van Rhee F (2008) A phase I study of CNTO 328, an anti-interleukin-6 monoclonal antibody in patients with B-cell non-hodgkin's lymphoma, multiple myeloma, or ccastleman's disease. Blood 112:Abstract 1009
89. Lacy MQ, Hayman SR, Gertz MA (2008) Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. Blood 112:Abstract 866
90. Locklin RM, Croucher PI, Russell RG, Edwards CM (2007) Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 21(4):805-812 (Pubitemid 46444566)
91. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11(1-2):32-50
92. Lacy M, Alsina M, Roberts L (2007) Phase I dose escalation study of the monoclonal antibody against the insulin like growth factor I receptor CP-751,871 in patients with multiple myeloma. Blood 110:Abstract 1171
93. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66(11):5781-5789 (Pubitemid 43927132)
94. Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, Garcia-Echeverria C, Zimmermann J, Pandiella A, San Miguel JF (2008) The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 141(4):470-482 (Pubitemid 351550551)
95. Mao X, Wood TW, Wang X, St-Germain J, Moran MF, Datti A, Wrana J, Batey RA, Schimmer AD (2008) A novel chromene-based pan-P13 kinase inhibitor displays perclinical activity in leukemia and myeloma. Blood 112:Abstract 1605
96. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1(3):194-202 (Pubitemid 33741894)
97. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N, Rosinol L, Montejano L, Blade J, Martinez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF (2008) Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 26(16):2737-2744
98. Mazumder A, Jagannath S, Vesole DH (2008) Treatment of multiple myeloma with vorinstat in combination with bortezomib: a case series. Blood 112:Abstract 5213
99. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Pea cock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821-831
100. McMillin DW, Delmore J, Negri JM, Hayden P, Mitsiades N, Richardson PG, Schlossman R, Munshi NC, Anderson KC, Mitsiades CS (2007) Activity of CDK1/2 inhibitor LCQ195 against multiple myeloma cells. Blood 110:Abstract 1519
101. Meinel F, Mandl-Weber S, Baumann P (2008) The novel NFkB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma cells and overcomes NFkB mediated drug resistance. Blood 2008:Abstract 1715
102. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21(37):5673-5683 (Pubitemid 35333000)
103. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101(10):4055-4062 (Pubitemid 36857886)
104. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garcia-Echeverria C, Pearson MA, Hofmann F, Anderson KC, Kung AL (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5(3):221-230 (Pubitemid 38402114)
105. Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL (2006) Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 107(1):397-403 (Pubitemid 43053569)
106. Moreau P, Hulin C, Facon T (2007) Phase I study of AVE1642 anti-IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Blood 110:Abstract 1171
107. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8):3148-3157 (Pubitemid 38451693)
108. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA (2007) National Cancer Research Institute Haematological Oncology Clinical Study Group. First -line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376 (9757):1989-1999
109. Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, Davies FE (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137(3):268-269 (Pubitemid 46537629)
110. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N (2008) Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and post-transcriptional levels. Cancer Res 68(13):5076-5085
111. Mughal T, Streetly MJ, Kazmi M, Smith M (2009) Response to thalidomide in patients with MM following disease progression with pomalidomide. Clin Lymphoma Myeloma 8(7):Abstract 616
112. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC et al (2008) Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118(2):491-504 (Pubitemid 351206540)
113. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC et al (2006) Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L),
114. Neri P, Tassone P, Shammas M, Yasui H, Schipani E, Batchu RB, Blotta S, Prabhala R, Catley L, Hamasaki M, Hideshima T, Chauhan D, Jacob GS, Picker D, Venuta S, Anderson KC, Munshi NC (2007) Biological pathways and in vivo antitumor activity induced by atiprimod in myeloma. Leukemia 21(12):2519-2526 (Pubitemid 350148896)
115. Ocio E, Maiso P, Garayoa M, Dupuis M, Pandieua A, San Miguel JF (2007) The activation of Fas receptor by APO010, a recombinant form of Fas ligand, induces in vitro and in vivo antimyeloma activity. Blood 120:Abstract 1515
116. O'Sullivan G, Leleu X, Jia X (2006) The combination of the mTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma. Blood 108:Abstract 3495
117. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC (1997) IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159(5):2212-2221 (Pubitemid 127681011)
118. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC (2008) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK. Blood 113(4):846-855
119. Orchard K, Cooper M, Lewington V, Tristram M, Zivanovic M, Thom J, Quadri S, Richardson D, Causer L, Johnson P (2008) Targeted radiotherapy in the conditioning prior to haematopoietic stem cell transplantation: results of a phase I radiation dose escalation study using yttrium-90-labelled anti-CD66 monoclonal antibody demonstrating high BM uptake of radiation. Blood 112:Abstract 2189
120. Orlowski R, Stewart K, Vallone M (2007a) Safety and antitumour efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematological malignancies: phase I results. Blood 110:Abstract 409
121. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL (2007b) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25):3892-3901 (Pubitemid 47477266)
122. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825-831 (Pubitemid 43363369)
123. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omede P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foa R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian multiple myeloma network. J Clin Oncol 25(28):4459-4465 (Pubitemid 350063804)
124. Park PU, Blanc V, Deckert J, Lejeune P, Bartle LM, Skaletskaya A, Mayo MF, Zhang C, Wetzel M-C, Tavares DJ, Lutz RJ, Chittenden T, Bissery M-C, Lambert JM, Goldmacher VS (2008) SAR650984: a potent anti-CD38 therapeutic antibody with three mechanisms of action (Apoptosis, ADCC, CDC) for hematological malignancies. Blood 112:Abstract 2756
125. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J (2006) Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 66(19):9714-9721 (Pubitemid 44623672)
126. Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, Rapp MJ, Harousseau JL, Amiot M, Bataille R (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 12(12):1977-1982 (Pubitemid 28554471)
127. Peters JM, Harris JR, Kleinschmidt JA (1991) Ultrastructure of the approximately 26 S complex containing the approximately 20 S cylinder particle (multicatalytic proteinase/proteasome). Eur J Cell Biol 56(2):422-432
128. Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105(4):1383-1395 (Pubitemid 40223651)
129. Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC (2004) GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103(9):3474-3479 (Pubitemid 38525680)
130. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC (2006) The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 103(51):19478-19483 (Pubitemid 46026056)
131. Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W et al (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German study group of hematology and oncology (OSHO). J Cancer Res Clin Oncol 132(4):205-212 (Pubitemid 43144255)
132. Ponisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D (2008) Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. Br J Haematol 143(2):191-200
133. Prince HM, Honemann D, Spencer A (2007) VEGF-R inhibition with pazopanib (GW786034) is ineffective in pretreated myeloma. Haematologica 92(Suppl 2):Abstract 602
134. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1996) Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish leukaemia group. Br J Haematol 92(2):370-374 (Pubitemid 26046510)
135. Qiang YW, Kopantzev E, Rudikoff S (2002) Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99(11):4138-4146 (Pubitemid 35332058)
136. Qing G, Yan P, Xiao G (2006) Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK). Cell Res 16(11):895-901 (Pubitemid 44764199)
137. Raje N, Kumar S, Hideshima T (2004) Combination of the mTOR inhibitor rapamycin and revlimid (CC-5013) has synergistic activity in multiple myeloma. Blood 104:Abstract 1492
138. Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H et al (2009) Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 23(5):961-970
139. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050-4053 (Pubitemid 41775908)
140. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 24(3):431-436 (Pubitemid 46630462)
141. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, Abonour R, Siegel D, Greipp P (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern cooperative oncology group. Blood 110:Abstract 74
142. Raschko M, Markovina S, Miyamoto S (2007) Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (Bev/Rev/Dex) for relapsed or refractory myeloma. Blood 110:Abstract 1173
143. Richardson PG, Chanan-Khan AA, Alsina M, Doss D, Landrigan B, Kettner D, Albitar M, Mitsiades C, Cropp GF, Johnson RG, Hannah AL, Anderson KC (2005a) Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): interim results of a phase 1 trial. Blood 106:Abstract 361
144. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D et al (2005b) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487-2498
145. Richardson P, Jagannath S, Raje N (2007a) Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. Blood 110:Abstract 2714
146. Richardson P, Jakubowiak A, Wolf J (2007b) Phase I/II report from a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma previously treated with bortezomib. Blood 110:Abstract 1170
147. Richardson P, Lonial S, Jakubowiak A, Krishnan A, Wolf J, Densmore J, Singhal S, Ghobrial I, Stephenson J, Mehta J, Colson K, Francis D, Kendall T, Obadike N, Sullivan K, Martin J, Hideshima T, Lai L, Sportelli P, Gardner L et al (2007c) Multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/ refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood 2007:Abstract 1164
148. Richardson PG, Chanan-Khan A, Lonial S, Krishman A, Carroll M, Cropp GF, Kersey K, Abitar M, Johnson RG, Hannah AL, Anderson KC (2007d). Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formula. Blood 110:Abstract 1165
149. Richardson PG, Mitsiades CS, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker JL, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson KC, Siegel DS (2007e) Final results of a phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Blood 110:Abstract 1179
150. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W et al (2007f) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10):3557-3560
151. Richardson D, Hodges E, Mani A, Orchard K (2008) CD66 expression on malignant and normal plasma cells: a potential target for therapy. Blood 112:Abstract 5073
152. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291-3310
153. Roodman GD (2008) Bone building with bortezomib. J Clin Invest 118(2):462-464
154. Rossi J-F, Manges RF, Sutherland HJ, Jagannath S, Voorhees P, Sonneveld P, Delforge M, Pegourie B, Alegre A, Rubia J, Police D, Bandekar R, Xie H, Orlowski RZ (2008) Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory myeloma. Blood 112:Abstract 867
155. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML (2008) A single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24(4):744-752
156. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906-917
157. San-Miguel JF, Dimopoulos M, Weber D (2007) Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis). Blood 110:Abstract 2712
158. Santo L, Vallet S, Hideshima T, Cirstea D, Pozzi S, Vaghela N, Ikeda H, Okawa Y, Gorgun G, Perrone G, Calabrese E, Squires MS, Ladetto M, Munshi NC, Boccadoro M, Anderson KC, Raje N (2008) AT7519, a novel small molecule multicyclin dependent kinase inhibitor, induces apoptosis in multiple myeloma VIA GSK3β. Blood 112:Abstract 251
159. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood 109(9):3915-3921 (Pubitemid 46641744)
160. Siegel DS, Krishnan A, Lonial S, Chatta G, Alsina M, Jagannath S, Richardson P, Hohl RJ, Lust JA, Bensinger W, Carrum G, Moreb J, Simic A, Barlogie B, Maziarz RT, Anderson KC, Lin J, Lowe A, Vetticaden S, Zhu J (2006) Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). Blood 108:Abstract 3580
161. Siegel D, Sezer O, San Miguel JF, Mateos M, Prosser I, Cavo M, Jalaluddin M, Hazell K, Bourquelot PM, Anderson KC (2008) A phase IB, multi-center, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. Blood 112:Abstract 2781
162. Siegel DS, Weber DM, Mitsiades C, Rizvi S, Howe J, Reiser D, Anderson KC, Richardson PG (2009) Vorinostat/lenalidomide/dexamethasone: a phase I study. Clin Lymphoma Myeloma 8(7):Abstract 241
163. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21):1565-1571
164. Singhal A, Jagannath S, Vij R, Lonial S (2009) Phase 1b study of elotuzumab (HuLuc63) in combination with lenalidomide in relapsed multiple myeloma. Clin Lymphoma Myeloma 8(7):Abstract 129
165. Somlo G, Bellamy W, Zimmerman T (2005) Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/ refractory multiple myeloma. Blood 106:Abstract 2571
166. Spencer A, Lomial S, Taylor K, Jalaluddin M, Hazell K, Bourquelot PM, San Miguel JF (2009) Panobinostat and lenalidomide combination phase I trial in myeloma. Clin Lymphoma Myeloma 8(7):Abstract 329
167. Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C (2002) Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 100(12):3925-3929 (Pubitemid 35396856)
168. Stevenson GT (2006) CD38 as a therapeutic target. Mol Med 12(11-12):345-346
169. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA (2008) Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141(1):41-51 (Pubitemid 351350609)
170. Stromberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, Jernberg-Wiklund H (2004) Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103(8):3138-3147 (Pubitemid 38451692)
171. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4):415-421 (Pubitemid 26249195)
172. Stuhmer T, Zollinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kortum M, Unzicker C, Jensen MR, Quadt C, Chene P, Schoepfer J, Garcia-Echeverria C, Einsele H, Wajant H, Bargou RC (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22(8):1604-1612
173. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104(18):7516-7521 (Pubitemid 47185938)
174. Sullivan D, Singhal S, Schuster M, Berenson J, Gimsing P, Wislöff F, Waage A, Alsina M, Gerwien R, Clarke A, Moller K, Ooi CE (2006) A phase II study of PXD101 in advanced multiple myeloma. Blood 108:Abstract 3583
175. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC (2003) CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101(7):2762-2769 (Pubitemid 36857641)
176. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64(8):2846-2852 (Pubitemid 38500624)
177. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC (2005) Immuno modulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 65(24):11712-11720 (Pubitemid 41821732)
178. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66(13):6675-6682 (Pubitemid 44085624)
179. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 110(5):1656-1663 (Pubitemid 47443984)
180. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H et al (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112(4):1329-1337
181. Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, Toyooka S, Zochbauer-Muller S, Drach J, Parikh G, Zheng Y, Feng Z, Kroft SH, Timmons C, McKenna RW, Gazdar AF (2004) DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 10(9):2928-2935 (Pubitemid 38619667)
182. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK (2008) Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 118(5):1750-1764 (Pubitemid 351632378)
183. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105(7):2941-2948 (Pubitemid 40446289)
184. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, Chumakov I, Singer Y, Chang H, Liang SB, Yayon A (2006) The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107(10):4039-4046 (Pubitemid 43726812)
185. Trudel S, Yang XZ, Li ZH, Liang S-B, Aftab DT (2007) Evaluation of XL999, a potent inhibitor of FGFR3, for the potential treatment of t(4;14) positive multiple myeloma. Blood 110:Abstract 2515
186. Tsitoura DC, Rothman PB (2004) Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest 113(4):619-627 (Pubitemid 38542511)
187. Tu Y, Gardner A, Lichtenstein A (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 60(23):6763-6770
188. Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M et al (2007) MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 110(10):3744-3752 (Pubitemid 350159645)
189. Vallet S, Mukherjee S, Vaghela N, Pozzi S, Santo L, Cirstea D, Fulciniti M, Rahemtullah A, Attar E, Guimaraes A, Xie W, Patel C, Schoonmaker J, Weller E, Hideshima T, Munshi NC, Seehra J, Scadden D, Anderson KC, Raje N (2008) Restoration of bone balance via activin a inhibition results in anti-myeloma activity. Blood 112:Abstract 645
190. van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B (2008) First thalidomide clinical trial in multiple myeloma: a decade. Blood 112(4):1035-1038
191. Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI (2007) Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res 67(10):4572-4577 (Pubitemid 46910161)
192. Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Smith J, Qian Y, Jun S (2007) An open-label, phase 2 trial of denosumab in the treatment of relapsed (R) or plateau-phase (PP) multiple myeloma (MM). Blood 110:Abstract 3604
193. Vij R, Orlowski R, Stewart AK, Jagannath S, Kukreti V, Taylor J, Fuhrman D, Cruickshank S, Schwartz R, Kunkel L, Siegel D, (MMRC) TMMRc (2009) Phase II study of carfilzomib in patients with relapsed myeloma (PX-171-004). Clin Lymphoma Myeloma 8(7):Abstract 493
194. Vucic D, Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13(20):5995-6000 (Pubitemid 350075054)
195. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM (2008a) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12):4445-4451
196. Wang X, Sinn AL, Suvannasankha A, Crean CD, Chen L, Zhang S, Liang J, Zhang G, Pollok KE, Abonour R, Sidor C, Bray MR, Farag SS (2008b) The novel aurora kinase inhibitor ENMD-2076 has potent single agent activity against multiple myeloma (MM) in vitro and in vivo, and shows synergistic activity in combination with lenalidomide. Blood 112:Abstract 3660
197. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133-2142 (Pubitemid 350146108)
198. Weber DM, Badros A, Jagannath S, Siegel D, Richon V, Rizvi S, Garvia-Vargas J, Reiser D, Anderson KC (2009) Vorinostat and bortezomib in relpased/refractory MM. Clin Lymphoma Myeloma 8(7):Abstract 242
199. Wierda WG, Chen R, Plunkett W, Coutre S, Badros AZ, Popplewell L, Siegel D, Sinha R, Harvey D, Fox J, Mahadocon K, Kegley P, M.G. Bolton (2008) A phase 1 trial of SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma. Blood 112:Abstract 3178
200. Wildes TM, Ruddell A, Gao F, Uy G, Cashen A, Abboud C, Westervelt P, Dipersio JF, Vij R (2007) The activity and toxicity of dasatinib in relapsed or plateau-phase multiple myeloma. Blood 110:Abstract 1182
201. Wolf JL, Siegel D, Matous J, Lonial S, Goldschmidt H, Schmitt S, Vij R, Malgalhaes-Silverman M, Abonour R, Jalaluddin M, Li M, Hazell K, Bourquelot PM, Mateos M-V, Anderson KC, Spencer A, Harousseau J-L, Bladé J (2008) A phase II study of oral panobinostat (LBH589) in adult patients with advnced refractory multiple myeloma. Blood 112:Abstract 2774
202. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109(5):2106-2111 (Pubitemid 46348212)
203. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8(4):393-412
204. Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G (2007) Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol 82(9):831-833 (Pubitemid 350194516)
205. Zeng S, Li ZH, Chesi M, Leung-Hagesteijn C, Liang S, Bergsagel PL, Trudel S (2008) Pre-clinical evaluation of a small molecule inhibitor of CDK1 as potential therapy for MYC expressing mutiple myeloma tumors. Blood 112:Abstract 3667
206. Zhukovsky EA, Horton H, Peipp M, Pong E, Bernett M, Karki S, Richards J, Chu S, Repp R, Desjarlais J (2008) An Fc-engineered huma nized anti-CD40 monoclonal antibody, XmAb5485, exhibits potent activity in vitro and in vivo against non-hodgkin lymphoma, chronic lymphocytic leukemia and multiple myeloma. Blood 112:Abstract 881
207. Zollinger A, Stuhmer T, Chatterjee M, Gattenlohner S, Haralambieva E, Muller-Hermelink HK, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 112(8):3403-3411